
Ensitrelvir PEP Lowers Viral Load in COVID-19 Breakthrough Infections
In a Q&A, Florin Draica, MD, MBA, explains the 72-hour PEP window for ensitrelvir, breakthrough infection data, and which patients to prioritize.
An exploratory analysis presented at IDWeek evaluated patients with breakthrough infections or baseline infections, further underscoring the importance of ensitrelvir’s (Xocova; Shionogi) 72-hour post-exposure window.1
The exploratory analysis stemming from the SCORPIO-PEP study found that although some recipients had breakthrough infections, a numerically low proportion developed severe symptoms when compared with the placebo.1 But determining who contracted COVID-19 after receiving the drug highlights a common conundrum of false positives with local tests versus central tests, Florin Draica, MD, MBA, US VP of medical affairs, said in an interview in The American Journal of Managed Care® (AJMC®).
In this Q&A Draica explains the importance of ensitrelvir’s 72-hour window and how clinicians and payers can help optimize testing to ensure the most vulnerable populations can access the drug.
This transcript was lightly edited for clarity.
AJMC: Why is the 72-hour window after a household member's symptoms begin so important for postexposure prophylaxis with ensitrelvir?
Draica: After somebody is exposed to somebody who's infected with COVID-19, the virus SARS-CoV-2 can begin to replicate and will begin to replicate very quickly, and do that before symptoms start. There's the incubation period in which the virus replicates. That period between exposure and symptom onset is really important because acting very quickly with an antiviral can help reduce the risk of developing symptomatic COVID-19. That's why
AJMC: The new exploratory analyses at
Draica: First of all, just to state that in the SCORPIO-PEP study, ensitrelvir demonstrated a statistically significant reduction of 67% in the proportion of household contacts who developed [symptomatic] COVID-19. Now, there were a few people who still developed COVID-19. Even when prophylaxis did not prevent infection, participants who received Xocova had about a 1.2 log10 lower mean peak viral RNA level. That's a very important level of reduction, and they also had lower symptom scores, and they had a numerically smaller proportion of patients with severe symptoms than the placebo recipients.
I also need to point out that these were exploratory subgroup analyses, so the results are descriptive. And just to add, Xocova is not approved for COVID-19 treatment in the US.
AJMC: Your systematic literature review found that acute COVID-19 was linked to worsening of chronic conditions like asthma, COPD, and chronic kidney disease. How should that evidence shape which exposed patients clinicians prioritize for postexposure prophylaxis?
Draica: Postexposure prophylaxis may be particularly important for people at greater risk of complications from
What our systematic review adds to the picture is that it shows acute COVID-19 can also exacerbate or worsen existing conditions, including asthma, COPD, and chronic kidney disease. Across the studies we reviewed, COVID-19 was associated with worsening, exacerbation, or relapse of underlying chronic conditions, spanning respiratory, neurological, cardiovascular, renal, and other diseases, and we found that COVID-19 infection, again, even if mild or moderate, was associated with reduced health-related quality of life and with increased health care resource utilization.
These findings reinforce the continued burden of COVID-19 and underscore the importance of prevention, especially among people living with chronic conditions. Preventing infections after a known exposure may be especially meaningful for patients who have more to lose clinically if they become infected.
References
1. IDWeek 2026: new exploratory analyses evaluate XOCOVA® (ensitrelvir) following COVID-19 exposure, including breakthrough infections and infections present at baseline. Shionogi. October 10, 2021. Accessed November 17, 2026.
Related to this article








